Hormone Receptor Positive Malignant Neoplasm Of Breast — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hormone receptor positive malignant neoplasm of breast. 47 active patents protecting 4 drugs from 4+ originators. First major cliff: 2039. Daily refresh.

4
Approved drugs
47
Active US patents
66/100
Avg vulnerability
$4.3B
Annual revenue covered

Originators in Hormone Receptor Positive Malignant Neoplasm Of Breast

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Besins Hlthcare 36 patents Eli Lilly 4 patents Novartis 4 patents Azurity 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hormone receptor positive malignant neoplasm of breast. Each bar = one year. Y-axis scaled to peak year (24 patents).

24
26
4
27
4
28
4
31
8
34
3
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Androgel
TESTOSTERONE
 Besins Hlthcare 36 72 — 2026-10-12
Verzenio
abemaciclib
 Eli Lilly 4 68 $3.7B 2031-09-28
Afinitor
everolimus
 Novartis 4 70 $600M 2028-07-01
Testosterone Cypionate
Testosterone Cypionate
 Azurity 3 52 — 2039-03-25

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8466137 Androgel method of use 85 2026-10-12
8741881 Androgel method of use 85 2026-10-12
8741881 Androgel method of use 85 2026-10-12
8466138 Androgel method of use 85 2026-10-12
8466137 Androgel method of use 85 2026-10-12
8466138 Androgel method of use 85 2026-10-12
8741881 Androgel method of use 85 2026-10-12
8466137 Androgel method of use 85 2026-10-12
8466138 Androgel method of use 85 2026-10-12
8419307 Androgel method of use 85 2027-02-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11642355 Testosterone Cypionate formulation 50 2039-03-25
11311554 Testosterone Cypionate formulation 50 2039-03-25
12138271 Testosterone Cypionate formulation 55 2039-03-25
11090312 Androgel method of use 62 2034-03-17
9295675 Androgel method of use 62 2034-02-11
9295675 Androgel method of use 62 2034-02-11
9662340 Androgel method of use 62 2034-02-11
9662340 Androgel method of use 62 2034-02-11
8486925 Androgel formulation 65 2026-10-12
8466136 Androgel formulation 65 2026-10-12

Related